Gastrointestinal cancer: Over the RAINBOW - Renaissance in antiangiogenesis

Nature Reviews Clinical Oncology

Volumn 12, Issue 1, 2015, Pages 7-8

  Lordick, Florian ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; CISPLATIN; DOCETAXEL; IRINOTECAN; LAPATINIB; PACLITAXEL; PLACEBO; RAMUCIRUMAB; TUMOR MARKER; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ADVERSE OUTCOME; ANTIANGIOGENIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FATIGUE; HUMAN; HYPERTENSION; LIFE EXPECTANCY; MONOTHERAPY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SCORING SYSTEM; SHORT SURVEY; STOMACH CANCER; TUMOR LOCALIZATION; ADENOCARCINOMA; ESOPHAGEAL NEOPLASMS; FEMALE; MALE; PROCEDURES; REMISSION; STOMACH NEOPLASMS;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; REMISSION INDUCTION; STOMACH NEOPLASMS;

EID: 84927175485     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.195     Document Type: Short Survey

References (10)

1. Suzuki, S. et al. Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptorβ phosphorylation, and microvessel density in gastric cancer. BMC Cancer 10, 659 (2010).
2. Ohtsu, A. et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J. Clin. Oncol. 29, 3968-3976 (2011).
3. Lordick, F. Gastrointestinal cancer: Salvage chemotherapy in gastric cancer-more than a straw? Nat. Rev. Clin. Oncol. 9, 312-313 (2012).
4. Wilke, H. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 15, 1224-1235 (2014).
5. Fuchs, C. S. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383, 31-39 (2014).
6. Li, J. et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-Arm, phase II trial. J. Clin. Oncol. 31, 3219-3225 (2013).
7. Okines, A. F. et al. Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. Ann. Oncol. 24, 702-709 (2013).
8. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202-209 (2014).
9. Yoon, H. H. et al. Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicentre phase 2 trial [abstract]. J. Clin. Oncol. 32 (Suppl.), a4004 (2014).
10. Lordick, F. et al. Unmet needs and challenges in gastric cancer: the way forward. Cancer Treat. Rev. 40, 692-700 (2014).